Literature DB >> 10340884

Positive iliac and obturator nodes in melanoma: survival and prognostic factors.

L J Strobbe1, A Jonk, A A Hart, O E Nieweg, B B Kroon.   

Abstract

BACKGROUND: The need for deep groin dissection when superficial nodes contain metastatic melanoma is controversial.
METHODS: A review of 362 therapeutic groin dissections performed at our tertiary referral center between 1961 and 1995 revealed 71 patients (20%) with positive iliac and/or obturator nodes. This group was analyzed for survival rates, prognostic factors for survival, regional tumor control, and morbidity.
RESULTS: Patients with involved deep nodes exhibited overall 5-year and 10-year survival rates of 24% (SE, 5%) and 20% (SE, 5%), respectively. Independent prognostic factors for survival were the number of positive iliac nodes (P = .0011), the Breslow thickness (P = .0069), and the site of the primary tumor (P = .0075). Patients with an unknown primary tumor seemed to have better prognoses. Seven patients (10%) experienced recurrence in the surgically treated groin. The short- and long-term morbidity rates (infection, 17%; skin flap necrosis, 15%; seroma, 17%; mild/ moderate lymphedema, 19%; severe lymphedema, 6%) compared well with those of other series studying inguinal as well as ilioinguinal dissections.
CONCLUSIONS: From the present study it can be concluded that removal of deep lymph node metastases is worthwhile, because one of every five such patients survives for 10 years. Prognostic factors for survival are the number of involved iliac nodes, the Breslow thickness, and the site of the primary tumor. Long-term regional tumor control can be obtained for 90% of the patients. The morbidity of an additional deep lymph node dissection is acceptable.

Entities:  

Mesh:

Year:  1999        PMID: 10340884     DOI: 10.1007/s10434-999-0255-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

Review 2.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

3.  Continuous local analgesic therapy reduces pain after radical inguinal/iliacal lymph node dissection.

Authors:  Heiko Neuss; Martin Schomaker; Wieland Raue; Gerold Koplin; Oliver Haase
Journal:  Langenbecks Arch Surg       Date:  2010-12-29       Impact factor: 3.445

4.  Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.

Authors:  Rebekah R White; Wilma E Stanley; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

5.  Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy.

Authors:  Lesly A Dossett; Nicholas B Castner; Julio M Pow-Sang; Andrea M Abbott; Vernon K Sondak; Amod A Sarnaik; Jonathan S Zager
Journal:  J Am Coll Surg       Date:  2016-01-14       Impact factor: 6.113

6.  The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).

Authors:  Mark B Faries; John F Thompson; Alistair Cochran; Robert Elashoff; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-Jing Wang; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2010-07-08       Impact factor: 5.344

7.  Melanoma with unknown primary: report and analysis of 24 patients.

Authors:  Rita Clerico; Ugo Bottoni; Giovanni Paolino; Marina Ambrifi; Paola Corsetti; Valeria Devirgiliis; Stefano Calvieri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

8.  Inguinopelvic lymphadenectomy following positive inguinal sentinel lymph node biopsy in melanoma: true frequency of synchronous pelvic metastases.

Authors:  Carrie K Chu; Keith A Delman; Grant W Carlson; Andrea C Hestley; Douglas R Murray
Journal:  Ann Surg Oncol       Date:  2011-05-04       Impact factor: 5.344

9.  Adjuvant radiation therapy in metastatic lymph nodes from melanoma.

Authors:  Jean-Emmanuel Bibault; Sylvain Dewas; Xavier Mirabel; Laurent Mortier; Nicolas Penel; Luc Vanseymortier; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-02-06       Impact factor: 3.481

10.  Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors.

Authors:  Nicola Mozzillo; Corrado Caracò; Ugo Marone; Gianluca Di Monta; Anna Crispo; Gerardo Botti; Maurizio Montella; Paolo Antonio Ascierto
Journal:  World J Surg Oncol       Date:  2013-02-04       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.